trending Market Intelligence /marketintelligence/en/news-insights/trending/0wllcl42mNUNcJTr_io_Dw2 content esgSubNav
In This List

UnitedHealth's Optum, DaVita agree to cut price of medical group deal

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


UnitedHealth's Optum, DaVita agree to cut price of medical group deal

UnitedHealth Group Inc.'s Optum and DaVita Inc. have agreed to cut the sale price of DaVita Medical Group to $4.34 billion.

Optum was initially slated to pay $4.90 billion for the business, which will be combined with its OptumCare division. But Optum and DaVita have agreed to amend their equity purchase agreement to lower the sale price due to underlying business performance and in order to acquire the Federal Trade Commission's approval.

The FTC approval is the final remaining regulatory approval necessary to close the transaction. On Nov. 28, the California Department of Managed Health Care approved the proposed transaction. The companies expect to close the transaction in the first quarter of 2019.

As a result of the change in sale price, DaVita expects to record a charge in the fourth quarter of about $200 million to $250 million.